PF-00489791
Code | Size | Price |
---|
TAR-T28360-1mg | 1mg | £227.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28360-5mg | 5mg | £416.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28360-10mg | 10mg | £581.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28360-25mg | 25mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28360-50mg | 50mg | £1,163.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T28360-100mg | 100mg | £1,540.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
PF-00489791, an inhibitor of phosphodiesterase type 5, enhances the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
CAS:
853003-48-2
Formula:
C20H28N8O4S
Molecular Weight:
476.56
Pathway:
Metabolism
Purity:
0.98
SMILES:
CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(nc(Nc3cc(C)ccn3)c12)N(C)CC
Target:
PDE
References
1. Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, Walley R, Grover-P?ez F, Perros-Huguet C, Rolph T, El Nahas M. Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. J Am Soc Nephrol. 2016 Apr 25. pii: ASN.2015050473. [Epub ahead of print] PubMed PMID: 27113485.
2. Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, Kanbay M. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015 Sep;47(9):1521-8. doi: 10.1007/s11255-015-1071-4. Epub 2015 Aug 5. Review. PubMed PMID: 26242375.
3. Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML. Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension. 2009 Jun;53(6):1091-7. doi: 10.1161/HYPERTENSIONAHA.109.132225. Epub 2009 Apr 27. PubMed PMID: 19398651.